{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '05-Aug-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 2.0', '1', 'Trial Summary', 'Title', 'Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer', '(FIRE-9 - PORT /AIO-KRK-0418)', 'Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy', 'of active post-resection/ablation therapy in patients with metastatic colorectal', 'cancer', 'Short title', 'mFOLFOXIRI/mFOLFOX-6 versus follow-up surveillance after definite treatment of', 'colorectal cancer metastases', 'Sponsor', 'Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Charit\u00e9platz 1', '10117 Berlin', 'Coordinating', 'Prof. Dr. med. Dominik Modest', 'investigator', 'Charit\u00e9 - Universit\u00e4tsmedizin Berlin', 'and', 'Medizinische Klinik mit Schwerpunkt H\u00e4matologie, Onkologie und', 'Representative', 'Tumorimmunologie am Campus Virchow Klinikum (CVK)', 'of the Sponsor', 'Augustenburger Platz 1', '13353 Berlin', 'Protocol code', 'FIRE-9 - PORT', 'AIO trial-no.', 'AIO-KRK-0418', 'EudraCT no', '2020-006144-18', 'Protocol', 'Protocol version 3.0 dated 28-Sep-2021', 'version and', 'version date', 'Investigational', '5-FU, leucovorin, irinotecan, oxaliplatin', 'medicinal', 'product(s)', 'Clinical trial', 'Phase III', 'phase', 'Number of', 'To be assessed for eligibility: n ~ 750', 'patients', 'To be assigned to the trial, i.e. recruited: n = 507 (338 Arm A/169 Arm B)', 'Number of trial', 'About 80 trial sites', 'sites', 'Indication', 'Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer', 'studied', 'Background', 'In Germany, colorectal cancer has a prevalence of 65-80/100.000, resulting in a total', 'and', 'of ~60.000 new cases every year. Up to 50% of patients develop metastases during', 'rationale', 'the course of their disease while 15-25% already present with synchronous', 'metastases at first diagnosis [Howlader et al., 2011]. The current 5-year mortality is', 'approximately 50% [Robert-Koch-Institut, 2019]. In Western Europe, the burden of', 'colorectal cancer is reported to be 211 (female) and 298 (male) disability-adjusted', 'life years (DALYs) on a population of 100.000 [Soerjomataram et al., 2012].', 'Patients with metastases from colorectal cancer (appr. 40-50% of all patients develop', 'metastases) can benefit from the resection or ablation of metastases, although', 'relapse occurs in the majority (appr. 70-80%) of these patients [Folprecht et al., 2014;', 'Kopetz et al., 2009; Nordlinger et al., 2008; Nordlinger et al., 2013; Van Cutsem et', 'al., 2016]. Clearly, a further reduction in relapse rates would improve the long-term', 'outcome of these patients.', 'Confidential', 'Page 12 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Unfortunately, additive/adjuvant therapy after local treatment of metastases is not', 'established by phase III trials. Accordingly, no standard of care treatment to improve', 'the relapse rates is available and the current S3-guideline for colorectal cancer does', 'not recommend additive chemotherapy due to insufficient evidence on its benefit.', 'The present clinical trial aims to generate the missing evidence that additive therapy', 'after resection or ablation of metastases may improve PFS and OS in patients with', 'colorectal cancer. This is of specific importance since both improvements in', 'localized, but also systemic therapies have resulted in increasing numbers of mCRC', 'patients undergoing resection and/or ablation of metastases [Kopetz et al., 2019;', 'Choti et al., 2016; Cremolini et al., 2015; Cremolini et al., 2017; Heinemann et al.,', '2014; Luo et al., 2014; Modest et al., 2018].', 'Objectives', 'Primary objective', 'To compare the efficacy of active additive chemotherapy after definitive', 'treatment of metastases to structured follow-up only', 'Secondary objectives', 'To compare efficacy, safety and patient reported quality of life (QoL) of active', 'treatment to structured follow-up only', 'Further secondary objective', 'Further anti-tumor treatment', 'Exploratory objectives', 'To identify and characterize molecularly-defined patient subgroups and correlate', 'their genetic and molecular tumor characteristics with clinical efficacy and toxicity', 'using tumor specimen and blood-based biomarker candidates.', 'Endpoints', 'Primary endpoint', 'Progression-free survival (PFS) time at the 24 months follow-up defined as', 'time from randomization to death or evidence of disease (whatever occurs first)', 'Secondary endpoints', 'Efficacy', 'PFS in patients with/without prior systemic therapy', 'PFS in patients with R1 vs R0 resected lesions as well as ablated vs. purely', 'resected lesions', 'Overall survival (OS)', 'Treatments (including efficacy) beyond study participation', 'Local control of lesions according to ablative technique (surgery VS. ablation VS.', 'radiation)', 'Safety', 'Type, incidence, severity, and causal relationship to active chemotherapy of', 'non-serious adverse events and serious adverse events (severity evaluated', 'according to CTCAE version 5.0)', 'Quality of life', 'Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L', 'Exploratory endpoints', 'Translational analyses including evaluation of tumor specimen of primary and/or', 'metastatic tissue as well as blood samples at different time points', 'Confidential', 'Page 13 of 79']\n\n###\n\n", "completion": "END"}